Featured content
Manufacturing therapies that evolve: what will it take to scale living medicines?
In this interview, Christian Roghi explores the manufacturing, quality control and regulatory challenges facing living medicines; from microbiome therapeutics to phage therapies and engineered bacteria, he reveals what is needed to bring these products to market at scale.
ArticleManaging nitrosamine toxicological risk in late-stage development
Alex Gauthier at Novartis reviews practical toxicological strategies for managing late-stage nitrosamine drug substance-related impurities (NDSRIs) while maintaining patient safety and development timelines.
ReportPharma Horizons: Formulation
Discover the key technologies, risk mitigation strategies and development considerations shaping modern pharmaceutical formulation — from early-stage selection through to commercial-scale manufacturing.
ArticleEuropean Pharmaceutical Review Issue 2 2026
EPR Issue 2 includes articles on manufacturing, drug formulation, microbiology, downstream bioprocessing, and more.
News
NewsMatthew Durdy to retire as CGT Catapult CEO in 2027
Matthew Durdy will step down in June 2027 after nearly 15 years with the organisation, including seven years as CEO, as the Board begins its search for a successor.
NewsPharmaLogic to acquire Lantheus CDMO business and manufacturing facility
The acquisition will expand PharmaLogic’s US radiopharmaceutical manufacturing capacity and establish a transatlantic platform for radioligand therapies.
NewsMHRA awards Innovation Passports to three investigational medicines
Three investigational treatments for Huntington’s disease, non-small cell lung cancer and Alzheimer’s disease have received Innovation Passports through the UK’s Innovative Licensing and Access Pathway (ILAP).
NewsThe EPR regulatory roundup: 2–6 November 2026
A weekly roundup of the latest regulatory developments affecting pharmaceutical research, development and manufacturing, from new guidance and legislative changes to significant medicine approvals.
From our partners
Large-scale AAV manufacturing for non-rare diseases
As AAV therapies move beyond rare disease indications, manufacturing scalability becomes critical. Learn how an integrated approach to process development can help reduce risk, improve yields, and prepare for commercial success.
Opinion and interviews
Manufacturing therapies that evolve: what will it take to scale living medicines?
In this interview, Christian Roghi explores the manufacturing, quality control and regulatory challenges facing living medicines; from microbiome therapeutics to phage therapies and engineered bacteria, he reveals what is needed to bring these products to market at scale.
Manufacturing the route: oral and injectable drug delivery
Jennifer Gattari of Pfizer CentreOne discusses how patient needs, evolving delivery formats and emerging manufacturing trends are shaping the pharmaceutical industry, from oral solid dose products to sterile injectables.
- Previous
- Next
Join now
Unlock exclusive industry insights
- Bookmark articles and resources to access anytime
- Enjoy free access to industry leading resources, webinars and insights
- Stay informed with the latest news and breakthroughs in drug discovery
- Receive updates and recommendations tailored to your research interests
Upcoming Webinars
Webinar
The impact of negative control stability on recombinant endotoxin testing
Discover how to achieve stable negative control (NC) performance for sensitive and precise recombinant endotoxin testing.
Webinar
Building quality and consistency into accelerated cell and gene therapy development
How can cell and gene therapy manufacturers move programmes forward faster without compromising quality, scalability or regulatory readiness?
The impact of negative control stability on recombinant endotoxin testing
Building quality and consistency into accelerated cell and gene therapy development
On-demand Webinars
- Previous
- Next
